Alnylam Pharmaceuticals | ALNY - Interest Expense On Debt

Stock Price
351.17
Daily Change
-0.63 -0.18%
Monthly
-11.73%
Yearly
29.58%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $44.4M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 44.4M 4.15M Sep/2025
Amgen USD 653M 32M Dec/2025
Arrowhead Research USD 21.69M 2.69M Sep/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Incyte USD 592K 2K Sep/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
Moderna USD 12.14B 12.13B Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 281M 8M Sep/2025
PTC Therapeutics USD 2.64B 2.61B Sep/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Sanofi EUR -25M 99.78M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Takeda JPY 123.63B 40.49B Dec/2025
Tectonic Therapeutic USD 277M 276.98M Sep/2025
Ultragenyx Pharmaceutical USD 14.15M 108K Sep/2025
Vertex Pharmaceuticals USD 3.3M 400K Sep/2025
Xencor USD 7.66M 578K Sep/2025